Phio Pharmaceuticals (PHIO) EPS (Basic) (2016 - 2021)
Phio Pharmaceuticals' EPS (Basic) history spans 10 years, with the latest figure at -$11.65 for Q4 2021.
- For Q4 2021, EPS (Basic) fell 2741.46% year-over-year to -$11.65; the TTM value through Dec 2021 reached -$12.45, down 402.02%, while the annual FY2024 figure was -$9.08, 80.58% up from the prior year.
- EPS (Basic) reached -$11.65 in Q4 2021 per PHIO's latest filing, down from -$0.28 in the prior quarter.
- In the past five years, EPS (Basic) ranged from a high of -$0.2 in Q2 2021 to a low of -$55.92 in Q4 2018.
- Average EPS (Basic) over 5 years is -$4.88, with a median of -$0.98 recorded in 2017.
- Peak YoY movement for EPS (Basic): tumbled 6803.7% in 2018, then skyrocketed 92.64% in 2020.
- A 5-year view of EPS (Basic) shows it stood at -$0.81 in 2017, then crashed by 6803.7% to -$55.92 in 2018, then skyrocketed by 91.72% to -$4.63 in 2019, then soared by 91.14% to -$0.41 in 2020, then crashed by 2741.46% to -$11.65 in 2021.
- Per Business Quant, the three most recent readings for PHIO's EPS (Basic) are -$11.65 (Q4 2021), -$0.28 (Q3 2021), and -$0.2 (Q2 2021).